Fuzheng Xiaoai Decoction 50 Cases of Syndrome Endocrine Treatment of Breast Cancer After Operation

SUN Xian-fu; LIU Hui; HE Ya-ning; LIU Chao-jun; CUI Shu-de

doi:10.11653/syfj2014020192

您当前的位置：

首页 >

文章列表页 >

Fuzheng Xiaoai Decoction 50 Cases of Syndrome Endocrine Treatment of Breast Cancer After Operation

更新时间：2024-01-04

- Fuzheng Xiaoai Decoction 50 Cases of Syndrome Endocrine Treatment of Breast Cancer After Operation
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 2, Pages: 192-195(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/syfj2014020192
  CLC：
- Published：2014
- 稿件说明：
移动端阅览
SUN Xian-fu, LIU Hui, HE Ya-ning, et al. Fuzheng Xiaoai Decoction 50 Cases of Syndrome Endocrine Treatment of Breast Cancer After Operation[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(2): 192-195.
DOI：

SUN Xian-fu, LIU Hui, HE Ya-ning, et al. Fuzheng Xiaoai Decoction 50 Cases of Syndrome Endocrine Treatment of Breast Cancer After Operation[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(2): 192-195. DOI： 10.11653/syfj2014020192.

摘要

目的：观察扶正消癌方对他莫昔芬（TAM）所致乳腺癌内分泌综合征的疗效及对乳腺癌患者生存质量的影响。方法：将100例患者随机按数字表法分为对照组和观察组各50例。对照组服用他莫昔芬（TAM），20 mg/次，1次/d，口服。观察组在对照组治疗的基础上加服扶正消癌方，1剂/d，连续服用2个月，症状改善后改为隔日1剂，再用2个月。并对所有患者随访3个月。采用改良Kupperman评分法评估临床主要症状积分；采用乳腺癌专用生存质量量表FACT-B（4.0）评价生存质量；记录治疗期和随访期内持续接受TAM治疗的例数。结果：治疗后观察组改良Kupperman评分明显下降（P<0.01），并低于对照组（P<0.01）；观察组症状积分改善率为80.0%优于对照组的12.0%（P<0.01）；治疗后观察组疾病控制率（DCR）为88.0%，优于对照组的72.0%（P<0.05）；观察组生存质量量表中生理状况和情感情况2个维度评分、特异条目评分及总分均较治疗前明显提高（P<0.01），并高于对照组（P<0.01）；观察组有6例（2.0%）无法坚持TAM治疗，低于对照组的19例（38.0%）（P<0.05）。结论：扶正消癌方能减轻乳腺癌内分泌综合征症状，提高患者TAM治疗依丛性，还能提高患者生存质量，使患者从中获益，值得临床使用。

Abstract

Objective: The purpose is to observe the curative effect of Fuzheng Xiaoai decoction in treatment of the breast cancer endocrine syndrome caused by tamoxifen (TAM) and its influence of life quality of breast cancer patients. Method: One hundred cases of patients were randomly divided into control group (50 cases) and observation group (50 cases) according to digital method. The patients in the control group took TAM

20 mg/time

1 time/day

orally. Based on the control group

patients in observation group took Fuzheng Xiaoai decoction additionally

1 dose/day

continued for 2 months. If the symptoms are improved

the frequency is changed to 1 dose every two days

continued 2 months. All the patients were followed up for 3 months. The modified Kupperman score method is used to evaluate the clinical main symptoms integral. The quality of life of patients with breast cancer-scale Functional Assessment of Cancer Therapy-Breast(FACT-B) (4.0) is used to evaluate quality of life

record the treatment and follow-up treatment cases during the continued TAM treatment period. Result: After the treatment

the modified Kupperman score of observation group significantly decreased(P<0.01) and was lower than the control group (P<0.01). The symptoms integral period of observation group was 80.0%

which is better than 12.0% of control group (P<0.01). Disease control rates (DCR) of observation group was 88.0%

which is better than 72.0% of control group (P<0.05). The physiological condition and emotional dimension score in the quality of life scale

specific entry score and total score of observation group were significantly improved (P<0.01) and were higher than the control group (P<0.01). There are 6 cases (2.0%) in observation group cannot keep TAM treatment

which is lower than 19 cases (38.0%) of control group (P<0.05). Conclusion: Fuzheng Xiaoai decoction can reduce breast cancer endocrine syndrome symptoms

improve compliance of patient in TAM treatment and improve the life quality of patients. It can make patients benefit and be worthy of clinical use.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Influence of Fuzheng Shugan Xiaoai Decoction on Relapse and Metastasis and Life Quality in Breast Cancer Patients with Postoperative Radiation and Chemotherapy

Exploring Mechanism of Breast Cancer Prevention by Liuwei Dihuangwan， Erzhiwan and Zuoguiwan Based on Macrophage Phagocytosis

Screening of Anti-breast Cancer Active Ingredients in Famous Classical Formula Yanghetang

Intervention of Breast Cancer by Regulating Wnt/β-catenin Signaling Pathway with Traditional Chinese Medicine： A Review

Role and Mechanism of Cucurbitacin B in Suppressing Proliferation of Breast Cancer 4T1 Cells via Inducing Ferroptosis

Related Author

LI Fu-xin

ZHENG Lixiang

CHEN Yishan

QUAN Wei

ZHONG Youbao

GUO Zifeng

SU Sijia

ZHAO Xinyu

Related Institution

Jiangxi University of Chinese Medicine

Dongfang Hospital， Beijing University of Chinese Medicine

The First Affiliated Hospital of Heilongjiang University of TCM

The First Clinical Medical College of Heilongjiang University of Traditional Chinese Medicine （TCM）

School of Chinese Material Medica， Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰